Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189915 · ClinicalTrials.gov registry record · NA
Open-Label Creatine Study for Female Meth Users
A NA study, sponsored by Perry Renshaw.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02189915 is a NA study that was terminated before completion, run by Perry Renshaw. The registered enrollment target is 14 participants.
The verdict
NCT02189915, a NA study, was terminated before completion, sponsored by Perry Renshaw.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Study Purposes and Objectives: The objectives should be stated in such a way that the reader can determine the appropriateness of the study design. If appropriate, state the specific hypotheses being tested and/or study aims. Use lay language. Methamphetamine use is of great concern in the state of Utah because it's the primary drug of threat in the state, and is the primary drug of choice among females between the ages of 18 and 24. The primary hypothesis of the study is that eight weeks of oral creatine supplementation will result in improvements in depression rating scores in female MA users. Secondary hypotheses include the following: 1) creatine supplementation will result in a decrease in the number of positive MA screens; 2) NAA and Cr concentrations will increase after eight weeks of oral creatine supplementation; and 3) PCr/β-NTP levels in the frontal lobe using 31P MRS will increase after eight weeks of creatine monohydrate oral supplementation.
Interventions
- DRUG Creatine monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02189915
The ClinicalTrials.gov registry entry for NCT02189915 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perry Renshaw, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Creatine monohydrate is the first listed.
NCT02189915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02189915 about?
NCT02189915 is a clinical study titled "Open-Label Creatine Study for Female Meth Users". Study Purposes and Objectives: The objectives should be stated in such a way that the reader can determine the appropriateness of the study design. If appropriate, state the specific hypotheses being tested and/or study aims. Use lay language. Methamphetamine use is of great concern in the state o...
What is the current status of trial NCT02189915?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2012-01. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02189915?
The interventions under investigation include: Creatine monohydrate (DRUG).
Who is sponsoring clinical trial NCT02189915?
This trial is sponsored by Perry Renshaw, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.